Abbott Laboratories Corporation

Jeffrey H Baxter

Pradip Mukerji

Anne C Voss

Michael John Tisdale

Michael J Tisdale

Terrence B Mazer

Joseph E Walton

Paul W Johns

Normanella Dewille

David R Wolf

Amy L Marchio

Vikkie Mustad

Megan Terp

Amy Devitt-Maicher

Emily Stepp

Youngsuk Heo

Amy Marchio

A liquid nutritional composition including 5-methyltetrahydrofolic acid (5-MTHF) is provided. The liquid nutritional composition also includes ascorbic acid and a protein system containing methionine to inhibit or reduce oxidation of the 5-MTHF and provide an active folate level of the liquid nutritional composition that remains stable over the shelf life of the liquid nutritional composition.

Liquid nutritional composition containing 5-methyltetrahydrofolic acid

Disclosed are nutritional compositions, and methods of using and making the nutritional compositions, that include calcium beta-hydroxy-beta-methylbutyrate and protein. The calcium beta-hydroxy-beta-methylbutyrate is in sequestered or ion-exchanged form to reduce the interaction of the calcium with the protein in the nutritional composition and improve the overall stability of the nutritional composition.

Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

Compositions including beta-hydroxy-beta-methylbutyrate

Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting

Method of using &#x3b2;-hydroxy-&#x3b2;-methylbutyrate for the treatment of disease conditions

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting

Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate

HMB uses thereof

Growing community of inventors

Gahanna, OH, United States of America

Jeffrey H Baxter